These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 23834232)

  • 1. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
    Bortlik M; Machkova N; Duricova D; Malickova K; Hrdlicka L; Lukas M; Kohout P; Shonova O; Lukas M
    Scand J Gastroenterol; 2013 Aug; 48(8):951-8. PubMed ID: 23834232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
    Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.
    Schnitzler F; Fidder H; Ferrante M; Ballet V; Noman M; Van Assche G; Spitz B; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
    Inflamm Bowel Dis; 2011 Sep; 17(9):1846-54. PubMed ID: 21830263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy.
    Zelinkova Z; de Haar C; de Ridder L; Pierik MJ; Kuipers EJ; Peppelenbosch MP; van der Woude CJ
    Aliment Pharmacol Ther; 2011 May; 33(9):1053-8. PubMed ID: 21366638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
    Casanova MJ; Chaparro M; Domènech E; Barreiro-de Acosta M; Bermejo F; Iglesias E; Gomollón F; Rodrigo L; Calvet X; Esteve M; García-Planella E; García-López S; Taxonera C; Calvo M; López M; Ginard D; Gómez-García M; Garrido E; Pérez-Calle JL; Beltrán B; Piqueras M; Saro C; Botella B; Dueñas C; Ponferrada A; Mañosa M; García-Sánchez V; Maté J; Gisbert JP
    Am J Gastroenterol; 2013 Mar; 108(3):433-40. PubMed ID: 23318480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
    Roblin X; Rinaudo M; Del Tedesco E; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Am J Gastroenterol; 2014 Aug; 109(8):1250-6. PubMed ID: 24913041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type.
    Kanis SL; de Lima-Karagiannis A; van der Ent C; Rizopoulos D; van der Woude CJ
    J Crohns Colitis; 2018 Jul; 12(8):939-947. PubMed ID: 29771301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.
    Mahadevan U; Cucchiara S; Hyams JS; Steinwurz F; Nuti F; Travis SP; Sandborn WJ; Colombel JF
    Am J Gastroenterol; 2011 Feb; 106(2):214-23; quiz 224. PubMed ID: 21157441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
    Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
    J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
    Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study.
    Coelho J; Beaugerie L; Colombel JF; Hébuterne X; Lerebours E; Lémann M; Baumer P; Cosnes J; Bourreille A; Gendre JP; Seksik P; Blain A; Metman EH; Nisard A; Cadiot G; Veyrac M; Coffin B; Dray X; Carrat F; Marteau P;
    Gut; 2011 Feb; 60(2):198-203. PubMed ID: 21115547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
    Flanagan E; Gibson PR; Wright EK; Moore GT; Sparrow MP; Connell W; Kamm MA; Begun J; Christensen B; De Cruz P; Shelton E; Dowling D; Andrews JM; Brown SJ; Niewiadomski O; Ward MG; Rosella O; Rosella G; Kiburg KV; Ross AL; Bell SJ;
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1551-1562. PubMed ID: 32981127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is safety infliximb during pregnancy in patients with inflammatory bowel disease?
    Argüelles-Arias F; Castro-Laria L; Barreiro-de Acosta M; García-Sánchez MV; Guerrero-Jiménez P; Gómez-García MR; Cordero-Ruiz P; Iglesias-Flores E; Gómez-Camacho F; Domínguez-Muñoz EJ; Herrerías-Gutiérrez JM
    Rev Esp Enferm Dig; 2012 Feb; 104(2):59-64. PubMed ID: 22372798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
    Julsgaard M; Christensen LA; Gibson PR; Gearry RB; Fallingborg J; Hvas CL; Bibby BM; Uldbjerg N; Connell WR; Rosella O; Grosen A; Brown SJ; Kjeldsen J; Wildt S; Svenningsen L; Sparrow MP; Walsh A; Connor SJ; Radford-Smith G; Lawrance IC; Andrews JM; Ellard K; Bell SJ
    Gastroenterology; 2016 Jul; 151(1):110-9. PubMed ID: 27063728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure to Infliximab During Pregnancy: Post-Marketing Experience.
    Geldhof A; Slater J; Clark M; Chandran U; Coppola D
    Drug Saf; 2020 Feb; 43(2):147-161. PubMed ID: 31677004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry.
    Chugh R; Long MD; Jiang Y; Weaver KN; Beaulieu DB; Scherl EJ; Mahadevan U
    Am J Gastroenterol; 2024 Mar; 119(3):468-476. PubMed ID: 37796648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.
    Khan N; Asim H; Lichtenstein GR
    Expert Opin Drug Saf; 2014 Dec; 13(12):1699-708. PubMed ID: 25406728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.
    Mahadevan U; Wolf DC; Dubinsky M; Cortot A; Lee SD; Siegel CA; Ullman T; Glover S; Valentine JF; Rubin DT; Miller J; Abreu MT
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):286-92; quiz e24. PubMed ID: 23200982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
    Riis A; Martinsen TC; Waldum HL; Fossmark R
    Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.